Maplight Therapeutics (NASDAQ:MPLT) Stock Price Up 4.8% – Still a Buy?

Maplight Therapeutics, Inc. (NASDAQ:MPLT) rose 4.8% during trading on Friday . The stock traded as high as $19.47 and last traded at $19.47. Approximately 21,903 shares were traded during mid-day trading, a decline of 88% from the average daily volume of 183,259 shares. The stock had previously closed at $18.58.

Wall Street Analysts Forecast Growth

MPLT has been the subject of several recent research reports. Wall Street Zen raised shares of Maplight Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, December 20th. Morgan Stanley began coverage on shares of Maplight Therapeutics in a report on Friday, November 21st. They set an “overweight” rating and a $34.00 target price for the company. Zacks Research upgraded shares of Maplight Therapeutics to a “hold” rating in a research report on Monday, November 24th. Leerink Partners started coverage on shares of Maplight Therapeutics in a research note on Friday, November 21st. They issued an “outperform” rating and a $30.00 target price for the company. Finally, Jefferies Financial Group started coverage on shares of Maplight Therapeutics in a report on Friday, November 21st. They set a “buy” rating and a $32.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $31.00.

Maplight Therapeutics Stock Performance

The business has a 50 day moving average of $17.10. The firm has a market capitalization of $850.69 million and a price-to-earnings ratio of -0.50.

Maplight Therapeutics (NASDAQ:MPLT) last posted its earnings results on Thursday, December 4th. The company reported ($37.18) EPS for the quarter, missing the consensus estimate of ($1.86) by ($35.32).

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.